Related Experiment Video
Updated: Jun 8, 2026

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke
Published on: January 18, 2018
Epidemiology, diagnosis and management of intracranial atherosclerotic disease
Jiann-Shing Jeng1, Sung-Chun Tang, Hon-Man Liu
1Department of Neurology, National Taiwan University Hospital, No. 7 Chung-Shan South Road, Taipei, Taiwan. jsjeng@ntu.edu.tw
Insights
Intracranial atherosclerotic disease (ICAD) increases stroke risk, especially in certain ethnicities. Antiplatelet drugs are preferred over anticoagulants, while angioplasty/stenting shows promise but needs long-term data.
Area of Science:
- Neurology
- Vascular Medicine
- Interventional Cardiology
Background:
- Intracranial atherosclerotic disease (ICAD) is a leading cause of ischemic stroke, disproportionately affecting Asian, black, and Hispanic populations.
- Key risk factors for ICAD include hypertension, diabetes mellitus, and metabolic syndrome, contributing to a significant annual stroke risk of 10–20% in patients.
- High-grade stenosis (70–99%) in ICAD patients elevates stroke recurrence risk, necessitating effective secondary prevention strategies.
Purpose of the Study:
- To review current understanding and treatment strategies for intracranial atherosclerotic disease (ICAD).
- To evaluate the role of antiplatelet therapy and emerging endovascular interventions like angioplasty and stenting in managing ICAD.
- To highlight the need for further research, particularly high-quality randomized trials, to establish long-term benefits of interventions.
Main Methods:
- Review of existing literature on intracranial atherosclerotic disease (ICAD) epidemiology, risk factors, and clinical outcomes.
- Analysis of current secondary prevention guidelines, focusing on antiplatelet versus anticoagulant therapy.
- Assessment of the efficacy and safety of endovascular treatments, including angioplasty and stenting for ICAD.
Main Results:
- Antiplatelet agents remain the primary medical treatment for ICAD, with limited evidence supporting anticoagulants.
- Angioplasty and stenting demonstrate high technical success and low periprocedural complication rates as an alternative to medical management.
- Moderate rates of in-stent restenosis and uncertain long-term benefits necessitate further investigation into endovascular approaches.
Conclusions:
- Effective secondary prevention for symptomatic ICAD patients is crucial due to high stroke recurrence rates.
- While angioplasty and stenting offer a promising alternative for ICAD, long-term outcomes and restenosis rates require further evaluation.
- High-quality randomized controlled trials comparing endovascular therapy with best medical therapy are essential for definitive treatment guidelines in ICAD.
Abstract:
Intracranial atherosclerotic disease (ICAD) is a major cause of ischemic stroke, with higher occurrence rates in Asian, black and Hispanic individuals than in white individuals. Important risk factors for ICAD include age, hypertension, diabetes mellitus and metabolic syndrome. ICAD patients have a 10–20% annual risk of stroke, with greater risk in patients with high-grade stenosis (70–99%). Given the high risk of stroke recurrence in symptomatic ICAD patients, effective secondary prevention strategies are needed. Currently, there is no strong evidence supporting the use of anticoagulants in ICAD patients; antiplatelet drugs are still the preferred medication. Recently, angioplasty and stenting for ICAD has emerged as an alternative approach to medical treatment, owing to high technical success rates and low risk of periprocedural complications. However, the rate of in-stent restenosis is moderate, and the long-term benefit of endovascular treatment is not well established. High-quality randomized trials comparing angioplasty/stenting with the best medical therapy in ICAD patients are anticipated.
Related Concept Videos
Atherosclerosis III: Management
Atherosclerosis IV: Nursing Management
Atherosclerosis II: Clinical Manifestations and Diagnostic Tests
Aneurysm III: Interprofessional Care
Ischemic Stroke l: Introduction
Atherosclerosis I: Introduction
